Founded in 2006, with registered capital of 20 million yuan, Sichuan Sunheal is committed to research, development, distribution of pharmaceutical product as well as the agency for overseas pharmaceutical companies. At present, the company system is running effectively with its sales network covering 32 provinces, municipalities and autonomous regions of China.
Sichuan Qingmu Pharmaceutical Co., Ltd. was established in May 2011, with registered capital of 80 million yuan, mainly engaged in the research, production and marketing of APIs and pharmaceutical intermediates. Designed by world-famous companies, Sichuan Qingmu Pharma is in line with the United States FDA, EU GMP and EHS requirement. More than 10 APIs have passed the CFDA on-site inspection and obtained the GMP certificate. Knock-out products Bisoprolol Fumarate, Ubenimex etc. have been registered in EU and Japan. We will always provide domestic and overseas customers with quality products and services.
Xizang Runhe Pharmaceutical Co., Ltd., a full subsidiary of Easton Biopharma, is established in 2015 with a registered capital of CNY 12 million. Xizang Runhe Pharma obtained Good Supply Practice (GSP) certification in April 2016 and mainly provides distribution of drug products for domestic customers.
Chengdu Shuode Pharmaceutical Co., Ltd., a full subsidiary of Easton Biopharma, is established in 2016 with a registered capital of CNY 100 million. It is in the process of construction.
Established in 2018 with a registered capital of CNY80 million, Chengdu Unovel Pharmaceutical Co., Ltd. is committed to the research and development of biological drugs.